Core Viewpoint - Taihe Cheng Medical (CCM) experienced a stock price increase of 6.79%, reaching $5.842 per share, with a total market capitalization of $28.9839 million as of August 26 [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company's net profit attributable to shareholders was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Core Insights - Taihe Cheng Medical (CCM) experienced a 2.12% increase in stock price, reaching $5.3 per share, with a total market capitalization of $26.2971 million as of August 19 [1] - For the fiscal year ending December 31, 2024, the company reported total revenue of 384 million RMB, a year-over-year decrease of 28.55%, and a net profit attributable to shareholders of -30.8 million RMB, a decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited is primarily engaged in medical services and was listed on the New York Stock Exchange in 2009, with recommendations from JP Morgan, Morgan Stanley, and CICC [1] - Established in 1997, the company specializes in cancer prevention, diagnosis, education, and research, offering third-party tumor imaging diagnosis and radiation therapy services, as well as operating specialized cancer hospitals and outpatient departments [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to build an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Core Viewpoint - Taihe Cheng Medical (CCM) experienced an 8.78% increase in stock price, reaching $5.439 per share, with a total market capitalization of $26.9863 million as of August 13 [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company's net profit attributable to shareholders was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, brand usage in Singapore and mainland China, and training for proton center operations [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Core Viewpoint - Taihe Cheng Medical (CCM) experienced a stock price increase of 2.04%, reaching $5.00 per share, with a total market capitalization of $24.81 million as of August 12 [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company's net profit attributable to shareholders was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Core Insights - Taihe Cheng Medical (CCM) experienced an intraday increase of 8.63%, closing at $5.54 per share with a total market capitalization of $27.4879 million [1] - As of December 31, 2024, the company's total revenue is projected to be 384 million RMB, reflecting a year-on-year decrease of 28.55%, while the net profit attributable to the parent company is expected to be -30.8 million RMB, a decline of 3.56% year-on-year [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services and is jointly recommended by JP Morgan, Morgan Stanley, and CICC [1] - Established in 1997, the company specializes in cancer prevention, diagnosis, education, and research, offering third-party tumor imaging diagnosis and radiation therapy services, as well as operating specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, brand usage in Singapore and mainland China, and the operation and training of proton centers [1] - The collaboration aims to build an international specialized cancer hospital based on a multidisciplinary diagnostic model and clinical research orientation, enhancing patient experience and improving cancer diagnosis and treatment standards in China [1]

Company Overview - Taihecheng Medical (CCM) experienced a 4.36% increase in stock price, reaching $5.27 per share, with a total market capitalization of $26.1483 million as of August 6 [1] - The company reported total revenue of 384 million RMB for the year ending December 31, 2024, representing a year-on-year decrease of 28.55% [1] - The net profit attributable to the parent company was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Business Operations - Taihecheng Medical Group Limited, listed on the New York Stock Exchange in 2009, focuses on medical services, particularly in cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihecheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research orientation, enhancing patient experience and improving cancer treatment standards in China [1]

Core Insights - Taihe Cheng Medical (CCM) opened with a 5.94% increase, reaching $5.35 per share, with a total market capitalization of $26.54 million [1] - As of December 31, 2024, the company's total revenue is projected to be 384 million RMB, a year-on-year decrease of 28.55%, while the net profit attributable to the parent company is expected to be -30.8 million RMB, a decrease of 3.56% year-on-year [1] Company Overview - Taihe Cheng Medical Group Co., Ltd. is a holding company primarily engaged in medical services, listed on the New York Stock Exchange in 2009, recommended by JP Morgan, Morgan Stanley, and CICC [1] - Established in 1997, the company specializes in cancer prevention, diagnosis, education, and research, offering third-party tumor imaging diagnosis and radiation therapy services, as well as operating specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, brand usage in Singapore and mainland China, and the operation and training of proton centers [1] - The collaboration aims to build an international specialized cancer hospital based on a multidisciplinary treatment model and clinical research orientation, enhancing patient experience and improving cancer treatment standards in China [1]

Core Viewpoint - Taihe Cheng Medical (CCM) experienced a stock price increase of 3.84% on August 5, closing at $5.545 per share, with a total market capitalization of $27.51 million [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company's net profit attributable to shareholders was -30.8 million RMB, reflecting a year-on-year decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng entered into a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to establish an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Core Viewpoint - Taihe Cheng Medical (CCM) experienced a 2.4% increase in stock price, reaching $5.345 per share, with a total market capitalization of $26.52 million as of July 30 [1] Financial Performance - As of December 31, 2024, Taihe Cheng Medical reported total revenue of 384 million RMB, a year-on-year decrease of 28.55% [1] - The company recorded a net profit attributable to shareholders of -30.8 million RMB, reflecting a year-on-year decline of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [1] - Established in 1997, the company provides third-party tumor imaging diagnosis and radiation therapy services, operates self-built cancer specialty hospitals, outpatient departments, independent imaging centers, and proton centers [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to develop an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]

Financial Performance - As of June 30, 2024, the total revenue of Taihe Cheng Medical (CCM) is 219 million RMB, representing a year-on-year decrease of 23.09% [1] - The net profit attributable to the parent company is -172 million RMB, showing a significant year-on-year decline of 89.33% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [2] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [2] - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center to enhance cancer treatment and research capabilities in China and Singapore [2]